Heat shock protein as molecular targets for breast cancer therapeutics

Journal of Breast Cancer

Volumn 14, Issue 3, 2011, Pages 167-174

  Kim, Lee Su ^a   Kim, Jun Ho ^a  

^a Hallym University College of Medicine   (South Korea)

Author keywords

Breast; Carcinoma; Chaperone; Heat; Shock

Indexed keywords

ALVESPIMYCIN; AUY 922; BIIB 021; CNF 2024; EXEMESTANE; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; LAPATINIB; LETROZOLE; PACLITAXEL; PU DZ8; PU H71; RADICICOL; RETASPIMYCIN; SNX 5422; STA 9090; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; LIVER TOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME;

EID: 80054752050     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2011.14.3.167     Document Type: Review

References (83)

1. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004;206:149-57.
2. Workman P Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007;1113:202-16.
3. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8(4 Suppl):S55-61.
4. Ritossa F. A new pufng pattern induced by temperature shock and DNP in drosophila. Cell Mol Life Sci 1962;18:571-3.
5. Ritossa F Discovery of the heat shock response. Cell Stress Chaperones 1996;1:97-8.
6. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
7. Welch WJ. The role of heat-shock proteins as molecular chaperones. CurrOpin Cell Biol 1991;3:1033-8.
8. Welch WJ, Feramisco JR. Purification of the major mammalian heat shock proteins. J Biol Chem 1982;257:14949-59.
9. Wu C. Heat shock transcription factors: structure and regulation. Annu Rev Cell Dev Biol 1995;11:441-69.
10. Lindquist S, Craig EA. Te heat-shock proteins. Annu Rev Genet 1988; 22:631-77.
11. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifer of carcinogenesis. Cell 2007;130:1005-18.
12. Min JN, Huang L, Zimonjic DB, Moskophidis D, Mvechi NF. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-defcient mouse model for spontaneous tumors. Oncogene 2007;26:5086-97.
13. Meng L, Gabai VL, Sherman MY. Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis. Oncogene 2010;29:5204-13.
14. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002;295:1852-8.
15. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 1993;85:1558-70.
16. Sreedhar AS, Kalmár E, Csermely P Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004;562:11 -5.
17. Joly AL, Wettstein G, Mgnot G, Ghiringhelli F, Garrido C. Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun 2010;2:238-47.
18. Khalil AA, Kabapy NF, Deraz SF, Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta 2011;1816:89-104.
19. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-me-diated protein folding in the cytosol. Nat Rev Mol Cell Biol 2004;5:781-91.
20. Didelot C, Lanneau D, Brunet M, Joly AL, De Tonel A, Chiosis G, et al. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr Med Chem 2007; 14:2839-47.
21. Jakob U, Gaestel M, Engel K, Buchner J. Small heat shock proteins are molecular chaperones. J Biol Chem 1993;268:1517-20.
22. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86-103.
23. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luq-mani YA. Clinical and biological signifcance of HSP89 alpha in human breast cancer. Int JCancer 1992;50:409-15.
24. Doshi BM, Hightower LE, Lee J. Te role of Hsp27 and actin in the regulation of movement in human cancer cells responding to heat shock. Cell Stress Chaperones 2009;14:445-57.
25. Arrigo AP, Paul C, Ducasse C, Manero F, Kretz-Remy C, Virot S, et al. Small stress proteins: novel negative modulators of apoptosis induced independently of reactive oxygen species. Prog Mol Subcell Biol 2002; 28:185-204.
26. Garrido C, Brunet M, Didelot C, Zermati Y Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006;5:2592-601.
27. Williams K, Chubb C, Huberman E, Giometti CS. Analysis of diferential protein expression in normal and neoplastic human breast epithelial cell lines. Electrophoresis 1998;19:333-43.
28. Myung JK, Afehi-Sadat L, Felizardo-Cabatic M, Slavc I, Lubec G. Expres-sional patterns of chaperones in ten human tumor cell lines. Proteome Sci 2004;2:8.
29. Brunet Simioni M, De Tonel A, Hammann A, Joly AL, Bossis G, Four-maux E, et al. Heat shock protein 27 is involved in SUMO-2/3 modif-cation of heat shock factor 1 and thereby modulates the transcription factor activity. Oncogene 2009;28:3332-44.
30. Mori-Iwamoto S, Kuramitsu Y Ryozawa S, Mkuria K, Fujimoto M, Maehara S, et al. Proteomics fnding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 2007; 31:1345-50.
31. Choi DH, Ha JS, Lee WH, Song JK, Kim GY Park JH, et al. Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett 2007;581:1649-56.
32. Hansen RK, Parra I, Lemieux P Oesterreich S, Hilsenbeck SG, Fuqua SA. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 1999;56:187-96.
33. Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY et al. Upregu-lated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 2008;8:286.
34. Kiang JG, Tsokos GC. Heat shock protein 70 kDa: molecular biology biochemistry, and physiology. Pharmacol Ter 1998;80:183-201.
35. Jäättelä M. Heat shock proteins as cellular lifeguards. Ann Med 1999; 31:261-71.
36. Wang Q, He Z, Zhang J, Wang Y Wang T, Tong S, et al. Over expression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect Prev 2005; 29:544-51.
37. Schaftzel E, Rüdiger S, Bukau B, Deuerling E Functional dissection of trigger factor and DnaK interactions with nascent polypeptides and thermally denatured proteins. Biol Chem 2001;382:1235-43.
38. Frydman J. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu Rev Biochem 2001;70:603-47.
39. Pratt WB, Tof DO. Regulation of signaling protein function and traffcking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111-33.
40. Young JC, Barral JM, Ulrich Hartl F. More than folding: localized functions of cytosolic chaperones. Trends Biochem Sci 2003;28:541-7.
41. Chiang HL, Terlecky SR, Plant CP, Dice JF. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science 1989;246:382-5.
42. Bercovich B, Stancovski I, Mayer A, Blumenfeld N, Laszlo A, Schwartz AL, et al. Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J Biol Chem 1997;272: 9002-10.
43. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004;23:2907-18.
44. Yaglom JA, Gabai VL, Sherman MY High levels of heat shock protein Hsp72 in cancer cells suppress default senescence pathways. Cancer Res 2007;67:2373-81.
45. Gabai VL, Meriin AB, Yaglom JA, Volloch VZ, Sherman MY. Role of Hsp70 in regulation of stress-kinase JNK implications in apoptosis and aging. FEBS Lett 1998;438:1-4.
46. Gabai VL, Budagova KR, Sherman MY Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 2005;24:3328-38.
47. Evans CG, Chang L, Gestwicki JE. Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem 2010;53:4585-602.
48. Bottoni P Giardina B, Scatena R. Proteomic profiling of heat shock proteins: an emerging molecular approach with direct pathophysiological and clinical implications. Proteomics Clin Appl 2009;3:636-53.
49. Powers MV Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008;14:250-62.
50. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;3:301-23.
51. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75.
52. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM. Te heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 2000;275:37181-6.
53. Söti C, Rácz A, Csermely P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem 2002;277:7066-75.
54. Garnier C, Laftte D, Tsvetkov PO, Barbier P, Leclerc-Devin J, Mllot JM, et al. Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem 2002;277:12208-14.
55. Wandinger SK, Richter K, Buchner J. Te Hsp90 chaperone machinery. J Biol Chem 2008;283:18473-7.
56. Powers MV, Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 2007;581:3758-69.
57. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
58. Connell P, Ballinger CA, Jiang J, Wu Y, Tompson LJ, Höhfeld J, et al. Te co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001;3:93-6.
59. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993;85:570-4.
60. Pandey P, Saleh A, Nakazawa A, Kumar S, Srinivasula SM, Kumar V, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9by heat shock protein 90. EMBO J 2000;19:4310-22.
61. Workman P. Altered states: selectively drugging the Hsp90 cancer chap-erone. Trends MolMed 2004;10:47-51.
62. Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygel-danamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005;65:4929-38.
63. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anticancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73.
64. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42:273-9.
65. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15.
66. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
67. Chiosis G. Discovery and development of purine-scafold Hsp90 inhibitors. Curr Top Med Chem 2006;6:1183-91.
68. He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, et al. Identification of potent water soluble purine-scafold inhibitors of the heat shock protein 90. J Med Chem 2006;49:381-90.
69. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008;14:240-8.
70. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008;10:R33.
71. Wang Y Trepel JB, Neckers LM, Giaccone G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 2010; 11:1466-76.
72. Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ter 2009;8:921-9.
73. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13 Suppl 1:S125-35.
74. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002;21:1159-66.
75. Münster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001;7:2228-36.
76. Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, et al. Activation of f-bronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 2008;261:108-19.
77. Kang HJ, Hong MK, Jung SK, Kim LS. The role of heat shock proteins 70/90 as potential molecular therapeutic targets in breast cancer. J Breast Cancer 2007;10:231-40.
78. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007;67:2932-7.
79. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, et al. HSP90 inhibition is efective in breast cancer: a phase II trial of tanespi-mycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17:5132-9.
80. Hanson BE, Vesole DH. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. Expert Opin Investig Drugs 2009;18:1375-83.
81. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, et al. Inhibitors of HSP90 block p95-HER2 signaling in trastuzumab-resistant tumors and suppress their growth. Oncogene 2010;29:325-34.
82. Wong C, Chen S. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance. Cancer Res 2009;69:8670-7.
83. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 2009;106:8368-73.